Inclusion Criteria:

- Histologically confirmed newly diagnosed non-small cell bronchogenic carcinoma

- Squamous cell

- Adenocarcinoma

- Large cell undifferentiated

- Bronchoalveolar

- Non-small cell carcinoma not otherwise stated

- Unresectable stage IIIA

- Mediastinal lymph node enlargement of at least 1 cm but less than 2 cm on
computed tomography (CT) scans must have mediastinotomy or thoracoscopy to rule
out resectability

OR

- Stage IIIB disease without significant pleural effusion

- Seen on CT scan only (not seen on chest x-ray) or does not reaccumulate after 1
thoracentesis and is cytologically negative

- Metastases to contralateral, mediastinal, or supraclavicular nodes allowed

- Bidimensionally measurable or evaluable disease

- 18 and over

- ECOG performance status 0-1

- Adequate hematopoietic, hepatic, and renal function obtained <=4 weeks prior to
registration:

- Platelet count at least 100,000/mm^3

- White Blood Cell (WBC) count at least 4,000/mm^3 OR absolute neutrophil count at
least 2,000/mm^3

- Bilirubin normal

- Serum glutamic oxaloacetic transaminase (SGOT) no greater than 2.5 times upper
limit of normal

- Creatinine no greater than 1.5 mg/dL OR creatinine clearance at least 60 mL/min

- Fertile patients must use 2 methods of effective contraception for 4 weeks prior to,
during, and for 4 weeks after study therapy

- Concurrent filgrastim (G-CSF) allowed for persistent neutropenia

Exclusion Criteria:

- Positive pregnancy test,pregnant or nursing

- Uncontrolled high blood pressure, unstable angina, congestive heart failure, or
myocardial infarction within the prior year

- Serious cardiac arrhythmias requiring medication

- Prior radiotherapy to only area of measurable or active tumor

- Less than 5 years since prior chemotherapy

- Other active malignancies

- Serious uncontrolled active infection

- Evidence of greater than grade 1 neuropathy by history or physical examination

- History of seizure disorders

- Contraindication to daily low-dose (81 mg/day) aspirin